ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Also in this 8-page issue: Richard Pazdur named director of FDA’s new Office of Oncology Drug Products.

April 22, 2005

Obituary: Martin Abeloff, 65, Cancer Center Director At Johns Hopkins.

September 21, 2007

Retrovirus Vaccination Is Feasible, Workshop Participants Conclude

May 3, 1985

NCCN Admits Two New Member Institutions

March 22, 2013

Xgeva Significantly Increases Bone Metastasis-Free Survival

May 27, 2011

713 Nurses Pass Certification exam At ONS Congress

July 8, 1988